PointR Data Merges into Mateon Therapeutics — Company Will Focus on Using Data Analysis and AI to Develop New Treatments
https://pixabay.com/en/notebook-work-girl-computer-woman-2386034/

PointR Data Merges into Mateon Therapeutics — Company Will Focus on Using Data Analysis and AI to Develop New Treatments

According to a press release from Mateon Therapeutics, Mateon's recent merger agreement with PointR Data establishes plans to combine the use of artificial intelligence and data collection for the development…

Continue Reading PointR Data Merges into Mateon Therapeutics — Company Will Focus on Using Data Analysis and AI to Develop New Treatments
Amicus Therapeutics Continue to Develop Investigative Treatments for Fabry, Pompe, and Batten Diseases
Pexels / Pixabay

Amicus Therapeutics Continue to Develop Investigative Treatments for Fabry, Pompe, and Batten Diseases

According to a publication from Fabry Disease News, Amicus Therapeutics has as many as 14 investigational drugs currently in development for the treatment of rare diseases including Fabry, Pompe, and…

Continue Reading Amicus Therapeutics Continue to Develop Investigative Treatments for Fabry, Pompe, and Batten Diseases
First Human Trial Completed for Experimental Scleroderma and Multiple Sclerosis Drug
stevepb / Pixabay

First Human Trial Completed for Experimental Scleroderma and Multiple Sclerosis Drug

According to a story from Financial Buzz, the drug developer Emerald Health Pharmaceuticals, Inc., recently announced that the company had completed a phase 1 clinical trial for its experimental drug…

Continue Reading First Human Trial Completed for Experimental Scleroderma and Multiple Sclerosis Drug
New Study Suggests as Many as Half of Systemic Sclerosis Patients Affected by Sarcopenia
jarmoluk / Pixabay

New Study Suggests as Many as Half of Systemic Sclerosis Patients Affected by Sarcopenia

According to a publication from Scleroderma News, a recent study published in Rheumatology International suggests that the majority of systemic sclerosis patients experience sarcopenia as a result of their condition. Perhaps…

Continue Reading New Study Suggests as Many as Half of Systemic Sclerosis Patients Affected by Sarcopenia

CTD Holdings Gives Presentation on Investigatory Niemann-Pick Type C Drug at Family Support and Medical Conference

According to a press release from CTD Holdings, a biotechnology company based in Gainesville, Florida, the Company recently presented data collected from their investigatory Niemann-Pick Disease treatment, Trappsol Cyclo, to…

Continue Reading CTD Holdings Gives Presentation on Investigatory Niemann-Pick Type C Drug at Family Support and Medical Conference
Experimental Treatment for Pancreatic Cancer has Earned Orphan Drug Designation
source: pixabay.com

Experimental Treatment for Pancreatic Cancer has Earned Orphan Drug Designation

According to a story from BioSpace, the biopharmaceutical company CrystalGenomics, Inc. recently announced that the US Food and Drug Administration (FDA) has granted the company's investigational drug candidate CG-745 Orphan…

Continue Reading Experimental Treatment for Pancreatic Cancer has Earned Orphan Drug Designation

The Isaac Foundation has Turned to Television to Get Their Mucopolysaccharidosis Message Heard

The Isaac Foundation The Isaac Foundation was established by a man named Andrew McFadyen. He created the organization in 2007 in honor of  his son who is diagnosed with the rare…

Continue Reading The Isaac Foundation has Turned to Television to Get Their Mucopolysaccharidosis Message Heard

Expectations For This Clinical Trial Were to Slow Down ALS Progression; Instead it Reversed One Man’s Symptoms

  According to a recent article published in News NWA, in 2017 Mark Bedwell, of Fort Smith, Arkansas had been told that based upon the rapid progression of his amyotrophic…

Continue Reading Expectations For This Clinical Trial Were to Slow Down ALS Progression; Instead it Reversed One Man’s Symptoms
The Drug Fasenra has Earned Orphan Drug Designation to Treat Eosinophilic Esophagitis
Pexels / Pixabay

The Drug Fasenra has Earned Orphan Drug Designation to Treat Eosinophilic Esophagitis

According to a story from Check Orphan, the biopharmaceutical company AstraZeneca recently announced that its drug benralizumab (marketed as Fasenra) has earned Orphan Drug designation from the US Food and…

Continue Reading The Drug Fasenra has Earned Orphan Drug Designation to Treat Eosinophilic Esophagitis

After Being Part of a Crucial Spinal Muscular Atrophy Trial, a Family’s Future Remains Uncertain

According to a story from Palo Alto Online, it was only a few months into the life of Aleksandr Kostanyan when parents Svetlana Sargsyan and Tigran Kostanyan realized that something…

Continue Reading After Being Part of a Crucial Spinal Muscular Atrophy Trial, a Family’s Future Remains Uncertain
Abivax Begins Enrollment in Phase 2b Study of Experimental Ulcerative Colitis Treatment
jarmoluk / Pixabay

Abivax Begins Enrollment in Phase 2b Study of Experimental Ulcerative Colitis Treatment

According to a press release from French biotechnology company Abivax, the Company has successfully begun recruitment for its phase 2b clinical study of ABX464, its experimental once-a-day ulcerative colitis medication.…

Continue Reading Abivax Begins Enrollment in Phase 2b Study of Experimental Ulcerative Colitis Treatment
ICYMI: With the FDA’s Third Approval for Tissue Agnostic Therapies, Oncologists are Headed to the Next Level in Cancer Treatment
source: pixabay.com

ICYMI: With the FDA’s Third Approval for Tissue Agnostic Therapies, Oncologists are Headed to the Next Level in Cancer Treatment

Since the 1940s oncologists have been focusing on tumors at the location in the body where the tumors originated. According to a recent FDA press release, this is the third…

Continue Reading ICYMI: With the FDA’s Third Approval for Tissue Agnostic Therapies, Oncologists are Headed to the Next Level in Cancer Treatment
Experimental Treatment for Immune Thrombocytopenia Begins Trials in China
kalhh / Pixabay

Experimental Treatment for Immune Thrombocytopenia Begins Trials in China

According to a story from uk.finance.yahoo.com, the company Hutchison China MediTech Limited ("Chi-Med") has recently kicked off a phase 1 clinical trial. This trial is testing the company's investigational drug…

Continue Reading Experimental Treatment for Immune Thrombocytopenia Begins Trials in China
Rapid Whole Genome Sequencing is Getting Patients With Rare Genetic Disorders Diagnosed More Quickly
xresch / Pixabay

Rapid Whole Genome Sequencing is Getting Patients With Rare Genetic Disorders Diagnosed More Quickly

According to a story from the National Center for Advancing Translational Sciences (NCATS), research supported by the center is making it possible for kids born with serious, rare genetic disorders…

Continue Reading Rapid Whole Genome Sequencing is Getting Patients With Rare Genetic Disorders Diagnosed More Quickly